HomeCompareKUBTF vs ABBV

KUBTF vs ABBV: Dividend Comparison 2026

KUBTF yields 2.21% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $42.9K in total portfolio value
10 years
KUBTF
KUBTF
● Live price
2.21%
Share price
$15.01
Annual div
$0.33
5Y div CAGR
38.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$59.4K
Annual income
$13,592.74
Full KUBTF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KUBTF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKUBTFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KUBTF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KUBTF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KUBTF
Annual income on $10K today (after 15% tax)
$188.12/yr
After 10yr DRIP, annual income (after tax)
$11,553.83/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $9,502.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KUBTF + ABBV for your $10,000?

KUBTF: 50%ABBV: 50%
100% ABBV50/50100% KUBTF
Portfolio after 10yr
$80.9K
Annual income
$19,182.25/yr
Blended yield
23.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KUBTF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
1.8
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KUBTF buys
0
ABBV buys
0
No recent congressional trades found for KUBTF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKUBTFABBV
Forward yield2.21%3.06%
Annual dividend / share$0.33$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR38.7%40.6%
Portfolio after 10y$59.4K$102.3K
Annual income after 10y$13,592.74$24,771.77
Total dividends collected$35.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: KUBTF vs ABBV ($10,000, DRIP)

YearKUBTF PortfolioKUBTF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,007$306.97$11,550$430.00$543.00ABBV
2$12,215$437.98$13,472$627.96$1.3KABBV
3$13,701$630.07$15,906$926.08$2.2KABBV
4$15,576$916.04$19,071$1,382.55$3.5KABBV
5$18,016$1,349.93$23,302$2,095.81$5.3KABBV
6$21,301$2,024.02$29,150$3,237.93$7.8KABBV
7$25,894$3,102.07$37,536$5,121.41$11.6KABBV
8$32,595$4,888.17$50,079$8,338.38$17.5KABBV
9$42,853$7,976.04$69,753$14,065.80$26.9KABBV
10$59,445$13,592.74$102,337$24,771.77$42.9KABBV

KUBTF vs ABBV: Complete Analysis 2026

KUBTFStock

Kubota Corporation manufactures and markets machinery and related solutions in the food, water, and environment markets in Japan, North America, Europe, Asia, and internationally. It operates in three segments: Farm & Industrial Machinery, Water & Environment, and Other. The Farm & Industrial Machinery segment offers tractors, power tillers, combine harvesters, rice transplanters, turf equipment, utility vehicles, other agricultural machinery, implements, attachments, post-harvest machinery, vegetable production equipment, and other agricultural equipment; cooperative drying, rice seedling, and gardening facilities; rice mill plants; scales, weighing and measuring control systems, and air purifiers; engines for farming, construction, industrial machinery, and generators; and mini excavators, wheel and skid steer loaders, compact track and, and other construction machinery related products. The Water & Environment segment provides ductile iron and plastic pipes, valves, and single stack drain fittings, as well as design and construction services; reformer and cracking tubes, hearth and steel mill rolls, TXAX friction materials, and spiral welded steel pipes; air-conditioning equipment; wastewater treatment equipment and plants, pumps and plants, membrane solutions, flue gas desulfurization apparatus, membrane methane fermentation plants, and bathtubs; and water purification, night-soil treatment, waste incinerating and melting, and waste shredding and sorting plants. The Other segment offers logistics; and roofing and siding materials. The company also engages in non-life insurance underwriting, finance leasing and factoring services, building maintenance, security guarding, transportation, storage, distribution, and cargo handling businesses; and export and import of repair parts related to farm equipment, engines, and construction machinery. It serves customers through a network of dealers. The company was founded in 1890 and is headquartered in Osaka, Japan.

Full KUBTF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KUBTF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KUBTF vs SCHDKUBTF vs JEPIKUBTF vs OKUBTF vs KOKUBTF vs MAINKUBTF vs JNJKUBTF vs MRKKUBTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.